Patents Issued in June 13, 2017
  • Patent number: 9675581
    Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 13, 2017
    Assignee: SVC Pharma LP
    Inventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
  • Patent number: 9675582
    Abstract: An all-natural active ingredient herbal compositions and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin, derivatives of artemisinin, berberine, capsaicin and Tinospora Cordifolia. When formulated in a gel cap, the composition can consist of only artemisinin, berberine, capsaicin, and Tinospora cordifolia. A blended mixture and inert ingredients, such as selected excipient compounds, are mixed together with artemisinin, berberine, capsaicin, and Tinospora cordifolia and compressed to form a single pill, tablet, or capsule for the treatment of Zika virus. A tablet or pill for children is formulated to be chewable.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: June 13, 2017
    Assignee: U.S. Phytotherapy, Inc.
    Inventor: Bob D. Rosen
  • Patent number: 9675583
    Abstract: Provided herein are compounds, such as compounds, of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: June 13, 2017
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 9675584
    Abstract: Disclosed herein are substituted pyrazinyl acrylic acids of Formula (II): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 13, 2017
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Michael Clare
  • Patent number: 9675585
    Abstract: The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 13, 2017
    Assignees: Ezra Pharma, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi
  • Patent number: 9675586
    Abstract: Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 13, 2017
    Assignee: Genentech, Inc.
    Inventors: Edna Chow Maneval, Boa Tran H. Truong, Isan Chen, Jeffrey H. Hager, Debasish F. Roychowdhury
  • Patent number: 9675587
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 9675588
    Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: June 13, 2017
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg
  • Patent number: 9675589
    Abstract: Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a ?-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Murugappan Muthukumar, Benjamin Mohr
  • Patent number: 9675590
    Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 13, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Olivier Hermine, Flavia Guillem, Jean-Benoit Arlet, Genevève Courtois, Michaela Fontenay
  • Patent number: 9675591
    Abstract: The present invention provides methods for treating seizure disorders. The method includes administering to a subject in need thereof 2-amino-6-trifluoromethylthio-benzothiazole, or a pharmaceutically acceptable salt thereof. Methods for the treatment of pain are also described.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: June 13, 2017
    Assignee: The Regents of the University of California
    Inventors: Heike Wulff, Nichole Coleman, David Paul Jenkins
  • Patent number: 9675592
    Abstract: Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignees: The University of Chicago, The Board of Regents of the University of Illinois
    Inventors: Robert S. Daum, Susan Boyle-Vavra, Michael E. Johnson
  • Patent number: 9675593
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: June 13, 2017
    Assignee: INTERMUNE, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
  • Patent number: 9675594
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 13, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Patent number: 9675595
    Abstract: A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: June 13, 2017
    Assignee: Novartis AG
    Inventors: Christine Fritsch, Xizhong Huang, Markus Boehm, Emmanuelle di Tomaso, Jan Cosaert
  • Patent number: 9675596
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—; —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: June 13, 2017
    Assignee: Baltic Bio AB
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • Patent number: 9675597
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 13, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 9675598
    Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: June 13, 2017
    Assignee: Sanochemia Pharmazeutika AG
    Inventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
  • Patent number: 9675599
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: June 13, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Patent number: 9675600
    Abstract: Methods of treating cancer related conditions using anamorelin are described.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: June 13, 2017
    Assignee: HELSINN HEALTHCARE SA
    Inventors: William Mann, John Friend, William Polvino, Suzan Allen, Ming Lu, Elizabeth Duus, Ruben Giorgino, Enrico Baroni
  • Patent number: 9675601
    Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: June 13, 2017
    Assignee: Pharmena Spólka Akcyjna (Pharmena S.A.)
    Inventors: Jerzy Gębicki, Stefan Chłopicki
  • Patent number: 9675602
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: June 13, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia, Chun-Su Yuan
  • Patent number: 9675603
    Abstract: Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-? suitable for oral dosage to treat subjects having PPAR-? mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-? mediated condition.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 13, 2017
    Assignee: InteKrin Therapeutics, Inc.
    Inventors: Kathleen M. Lee, Linda Higgins, Dennis Lanfear
  • Patent number: 9675604
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 13, 2017
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventor: Guochuan Emil Tsai
  • Patent number: 9675605
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: June 13, 2017
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventors: Jillian Basinger, Graeme Freestone, Varsha Gupta, Alan Kaplan, Chi Ching Mak, Benjamin Pratt, Vincent Santora, Dipanjan Sengupta, Lino Valdez
  • Patent number: 9675606
    Abstract: The invention relates to the compounds of general formula (I): Preparation process and therapeutic use.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 13, 2017
    Assignee: SANOFI
    Inventors: Alain Braun, Olivier Duclos, Gilbert Lassalle, Franz Lorge, Valerie Martin, Olaf Ritzeler, Aurelie Strub
  • Patent number: 9675607
    Abstract: Methods and compositions are described for enhancing tissue regeneration or wound repair in a mammalian subject comprising a composition comprising (a) a proline hydroxylase inhibitor component or molecule that increases or upregulates HIF1a and (b) a carrier component comprising a hydrogel.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 13, 2017
    Assignees: Northwestern University, The Wistar Institute of Anatomy and Biology
    Inventors: Phillip B. Messersmith, Iossif A. Strehin, Ellen Heber-Katz
  • Patent number: 9675608
    Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 13, 2017
    Assignee: Macau University of Science and Technology
    Inventors: Kam Wai Wong, Yuen Kwan Law, Liang Liu
  • Patent number: 9675609
    Abstract: A pharmaceutical composition is provided having particles of a physical mixture that contain at least one 20-camptothecin or a derivative thereof, at least one surfactant, at least one stabilizer, and at least one diluent. The particles have a mean particle size of less than about 2500 nm. The pharmaceutical composition can be nano- or micro-sized particles containing the 20-camptothecin esters or derivatives thereof as part of a physical mixture, which can provide the active compound in a water-soluble/dispersible, bioavailable form. The particles can be used as an oral pharmaceutical composition which comprises the nano- or micro-sized form of 20-camptothecin esters or derivatives, such as in an oral suspension (e.g., an aqueous suspension), or capsules, or caplets. The pharmaceutical composition can be used in the treatment of a cancer or malignant tumor in a patient by oral administration thereof in a therapeutically effective amount.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: June 13, 2017
    Assignee: Cao Pharmaceuticals Inc.
    Inventors: Wenhao Chen, Jiyao Zhang, Zhisong Cao
  • Patent number: 9675610
    Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 13, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Johannes Bartholomaeus, Heinrich Kugelmann
  • Patent number: 9675611
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 13, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • Patent number: 9675612
    Abstract: The present invention relates to substituted thiazolopyrimidine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: June 13, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Klar, Lars Wortmann, Keith Graham, Florian Puehler, Detlev Sülzle, Georg Kettschau, Philip Lienau
  • Patent number: 9675613
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: June 13, 2017
    Assignee: Hikma Pharmaceuticals LLC
    Inventor: Murray Ducharme
  • Patent number: 9675614
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 13, 2017
    Assignee: Epizyme, Inc.
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin
  • Patent number: 9675615
    Abstract: Use of 2,3-dihydroquinazolin-4(1H)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: June 13, 2017
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, The Board of Regents of the University of Texas System
    Inventors: Daniel Gillet, Julien Barbier, Robert Davey, Jean-Christophe Cintrat, Romain Noel
  • Patent number: 9675616
    Abstract: The present invention relates to substituted phenoxypyridine compounds of general formula (I); in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: June 13, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: William Johnston Scott, Orlin Petrov, Manfred Möwes, Ningshu Liu, Ulf Bömer
  • Patent number: 9675617
    Abstract: The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: June 13, 2017
    Assignee: ISOFOL MEDICAL AB
    Inventors: Bengt Gustavsson, Björn Carlsson
  • Patent number: 9675618
    Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 13, 2017
    Assignee: Infirst Healthcare Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 9675619
    Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 13, 2017
    Assignee: Strategic Science & Technologies, LLC
    Inventor: Eric T. Fossel
  • Patent number: 9675620
    Abstract: A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Jean C. Shih, Florence M. Hofman, Thomas C. Chen
  • Patent number: 9675621
    Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 13, 2017
    Assignee: WISTA LABORATORIES LTD.
    Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
  • Patent number: 9675622
    Abstract: A method of contraception in a female is provided. The method includes administering to the female daily for a first number of successive days an oral combination drug formulation of a progestin and an estrogen. The oral combination drug formulation is administered in a multiphasic dosing regimen comprising a second number of phases with duration of each phase is a third number of days. The doses of each of the progestin and estrogen in each subsequent phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the progestin and estrogen administered during immediately preceding phase of the regimen. The ratio of a daily dose of progestin to a daily dose of estrogen is maintained at a constant level during the entire dosing period. The first number of successive days period is followed by a fourth number of days without progestin and estrogen administration.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 13, 2017
    Assignee: Arstat, Inc.
    Inventor: Arkady Rubin
  • Patent number: 9675623
    Abstract: The invention provides inhibitors of ?-crystallin aggregation and methods of using ?-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: June 13, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jason E. Gestwicki, Kathryn McMenimen, Leah Makley
  • Patent number: 9675624
    Abstract: The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of the androstane series and levocabastine, an H1 antagonist/anti-allergic, and also relates to therapeutic uses thereof, particularly for the treatment of inflammatory and allergic conditions, specifically rhinitis.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: June 13, 2017
    Assignee: Glaxo Group Limited
    Inventors: Diane Michele Ignar, Daren Scott Levin
  • Patent number: 9675625
    Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 13, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sakai, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
  • Patent number: 9675626
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 13, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9675627
    Abstract: Described herein are dosing regimens and kits for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: June 13, 2017
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Brandon Alan Wustman
  • Patent number: 9675628
    Abstract: The method for producing a mixture of neutral oligosaccharides extracted from flaxseed includes oligosaccharides having high molar masses generated by fractionation by ultrafiltration at a cut-off of between 15,000 and 50,000 Da and between 5,000 and 15,000 Da. The mixture of oligosaccharides produced as a result of the implementation of the method, and to the applications of the mixture can be used for skin repair and skin aging control.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 13, 2017
    Assignees: UNIVERSITE DE REIMS CHAMPAGNE ARDENNE, CENTRE VALORISATION GLUCIDES PROD NAT, UNIVERSITE DE ROUEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Francois Maquart, Georges Bellon, Claire Marchal, Helene Ducatel, Olivier Dupuis, Luc Picton, Didier Lecerf, Renauld Forbice
  • Patent number: 9675629
    Abstract: The present invention relates to a pH-responsive metal-catechol derivative nanoparticle for drug delivery based on a mussel adhesive protein, particularly Fe(III)-DOPA nanoparticle, and a method for preparing the same. A nanoparticle for drug delivery according to the present invention is prepared using a pH responsive substance, catechol derivative-metal complex, particularly Fe(III)-DOPA complex, based on a mussel adhesive protein. Thereby, the present invention has excellent biocompatibility, is capable of easily and quickly penetrating into a target cell, and releases a loaded drug under acidic conditions, which enables to selectively deliver a drug to a specific disease having an acidic environment.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: June 13, 2017
    Assignee: Postech Academy-Industry Foundation
    Inventors: Hyung Joon Cha, Bum Jin Kim, Ho gyun Cheong
  • Patent number: 9675630
    Abstract: The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing A-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and/or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and/or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional NO modulating agent and/or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: June 13, 2017
    Assignee: MARS, INCORPORATED
    Inventors: Harold H. Schmitz, Catherine L. Kwik-Uribe, Mark A. Kelm, John F. Hammerstone, Jr.